Susana M. Campos, MD, MPH

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.

Key opinion leaders examine promising antibody-drug conjugates (ADCs) in the pharmaceutical development pipeline.

Expert clinicians offer strategic guidance on optimal sequencing of antibody-drug conjugates (ADCs) in treatment protocols.

Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.

A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.

Although there have been numerous studies evaluating the role of different therapy schedules, cytotoxic agents, and routes of administration in ovarian cancer, the backbone of therapy remains a combination of a platinum and a taxane.